---
title: "Taysha Gene Therapies holders approve raising authorized shares to 700,000,000"
url: "https://aibio.space/news/taysha-gene-therapies-holders-approve-raising-authorized-shares-700/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-06-03"
section: "Listings"
tickers: "NASDAQ:TSHA"
source: "https://www.sec.gov/Archives/edgar/data/1806310/000119312525133745/d843671d8k.htm"
summary: "Common stock authorized rises from 400,000,000 shares. The company filed the amendment in Delaware on June 2, 2025."
---

By the aibio.space news desk.

Sources

- [Taysha Gene Therapies, Inc. 8-K (2025-06-03)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525133745/d843671d8k.htm)

[TSHA](https://aibio.space/companies/taysha-gene-therapies/)

2025-06-03

# Taysha Gene Therapies holders approve raising authorized shares to 700,000,000

Tickers [TSHA](https://aibio.space/companies/taysha-gene-therapies/)

Common stock authorized rises from 400,000,000 shares. The company filed the amendment in Delaware on June 2, 2025.

## Key facts

- **Company**: Taysha Gene Therapies, Inc. (NASDAQ: TSHA)

- **News type**: Listings

- **Primary source**: [Taysha Gene Therapies, Inc. 8-K (2025-06-03)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525133745/d843671d8k.htm)

*The facade of a neoclassical court building at dusk. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.*

Taysha Gene Therapies, Inc. ([TSHA](https://aibio.space/companies/taysha-gene-therapies/)) stockholders approved an amendment to the company's Amended and Restated Certificate of Incorporation that increases authorized common stock from 400,000,000 shares to 700,000,000 shares. The vote took place at the 2025 annual meeting on June 2, 2025. The company filed the amendment with the Secretary of State of the State of Delaware the same day.

Authorized shares are the maximum a company can issue. The proposal received 171,348,017 votes for, 8,177,868 against and 89,390 abstentions. Of the 205,054,570 shares outstanding as of the record date, 179,615,275 shares, or approximately 87%, were present or represented by proxy.

Stockholders also elected Phillip B. Donenberg, CPA, and Sukumar Nagendran, M.D., as directors to serve until the 2028 annual meeting of stockholders. They ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with 179,419,717 votes for.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

TSHA

Taysha Gene Therapies, Inc.

NASDAQ · United States

Open the starter desk

## More in Listings

Listings

### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/)

Oct 29, 2026

Listings

### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/)

Oct 29, 2026

Listings

### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/)

Oct 28, 2026

---
Source page: https://aibio.space/news/taysha-gene-therapies-holders-approve-raising-authorized-shares-700/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Taysha Gene Therapies holders approve raising authorized shares to 700,000,000", 2025-06-03, https://aibio.space/news/taysha-gene-therapies-holders-approve-raising-authorized-shares-700/